{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T13:17:07Z","timestamp":1765459027455,"version":"3.46.0"},"reference-count":40,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Science OA"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/20565623.2025.2528523","type":"journal-article","created":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T17:14:47Z","timestamp":1752340487000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of frontline doublet or triplet regimen initiation in transplant-ineligible newly diagnosed multiple myeloma"],"prefix":"10.1080","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9295-9750","authenticated-orcid":false,"given":"Matthew J.","family":"Pianko","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology\/Oncology, University of Michigan","place":["Ann Arbor, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niodita","family":"Gupta-Werner","sequence":"additional","affiliation":[{"name":"Johnson and Johnson Innovative Medicine, US Medical Affairs","place":["Horsham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0060-765X","authenticated-orcid":false,"given":"Bruno","family":"Emond","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc","place":["Montr\u00e9al, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Lefebvre","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc","place":["Montr\u00e9al, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Lafeuille","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc","place":["Montr\u00e9al, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annelore","family":"Cortoos","sequence":"additional","affiliation":[{"name":"Johnson and Johnson Innovative Medicine, US Medical Affairs","place":["Horsham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuchita","family":"Kaila","sequence":"additional","affiliation":[{"name":"Johnson and Johnson Innovative Medicine, US Medical Affairs","place":["Horsham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,7,12]]},"reference":[{"key":"e_1_3_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.46"},{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f3863"},{"key":"e_1_3_8_4_1","unstructured":"Surveillance Epidemiology and End Results (SEER). Cancer Stat Facts: Myeloma; 2023. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0205-9"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0098-9"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1827253"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2698"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4137"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00466-6"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31594-X"},{"key":"e_1_3_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0311-8"},{"key":"e_1_3_8_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1418856"},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590"},{"key":"e_1_3_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01488-8"},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008787"},{"key":"e_1_3_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103504"},{"key":"e_1_3_8_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.82"},{"key":"e_1_3_8_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"},{"key":"e_1_3_8_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1555460"},{"key":"e_1_3_8_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-208241"},{"key":"e_1_3_8_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.2949.2949"},{"issue":"1","key":"e_1_3_8_36_1","first-page":"8","article-title":"NCCN Guidelines\u00ae insights: multiple myeloma, version 3.2022: featured updates to the NCCN guidelines","volume":"20","author":"Callander NS","year":"2022","unstructured":"Callander NS, Baljevic M, Adekola K, et\u00a0al. NCCN Guidelines\u00ae insights: multiple myeloma, version 3.2022: featured updates to the NCCN guidelines. JNCCN. 2022;20(1):8\u201319.","journal-title":"JNCCN"},{"key":"e_1_3_8_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq433"},{"key":"e_1_3_8_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0539-0"},{"key":"e_1_3_8_39_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-publhealth-040119-094437"},{"key":"e_1_3_8_40_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010933404324"},{"key":"e_1_3_8_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-6849-3"},{"key":"e_1_3_8_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bty373"},{"key":"e_1_3_8_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181ec173d"},{"key":"e_1_3_8_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000936164.84357.ed"},{"key":"e_1_3_8_45_1","volume-title":"21st International Myeloma Society (IMS) Annual Meeting","author":"Usmani SZ","year":"2024","unstructured":"Usmani SZ, T F VH. Daratumumab SC\u2009+\u2009bortezomib\/lenalidomide\/dexamethasone in patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: results of the phase 3 CEPHEUS study. In: 21st International Myeloma Society (IMS) Annual Meeting. Brazil: Rio de Janeiro; 2024."},{"key":"e_1_3_8_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400712"},{"key":"e_1_3_8_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159933"},{"key":"e_1_3_8_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8054"},{"key":"e_1_3_8_49_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.28.1.160"},{"key":"e_1_3_8_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23229"},{"key":"e_1_3_8_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_320105"},{"key":"e_1_3_8_52_1","doi-asserted-by":"publisher","DOI":"10.1257\/jep.31.2.87"},{"key":"e_1_3_8_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.patter.2021.100392"}],"container-title":["Future Science OA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/20565623.2025.2528523","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T13:10:13Z","timestamp":1765458613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/20565623.2025.2528523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,12]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/20565623.2025.2528523"],"URL":"https:\/\/doi.org\/10.1080\/20565623.2025.2528523","relation":{},"ISSN":["2056-5623"],"issn-type":[{"type":"electronic","value":"2056-5623"}],"subject":[],"published":{"date-parts":[[2025,7,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifso20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifso20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-10-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2528523"}}